论文部分内容阅读
目的观察紫杉醇联合顺铂治疗晚期食管癌的安全性及临床疗效。方法选择2010年1月至2011年7月河南大学附属南石医院肿瘤科收治的98例晚期食管癌门诊住院患者,并随机分为治疗组与对照组,每组49例。治疗组给予紫杉醇联合顺铂治疗,对照组给予顺铂联合氟尿嘧啶治疗,观察两组治疗效果及不良反应情况。结果治疗组49例中完全缓解16例,部分缓解20例,稳定3例,进展10例;对照组49例中完全缓解12例,部分缓解14例,稳定10例,进展13例。治疗组治疗总有效率为73.5%,对照组为53.0%,治疗组明显优于对照组,差异有统计学意义(P<0.05)。结论紫杉醇联合顺铂治疗晚期食管癌临床疗效确切且安全性高,值得进一步推广应用。
Objective To observe the safety and clinical efficacy of paclitaxel plus cisplatin in the treatment of advanced esophageal cancer. Methods From January 2010 to July 2011, 98 patients with advanced esophageal cancer inpatients admitted to Department of Oncology, Nanshi Hospital, Henan University were randomly divided into treatment group and control group, with 49 cases in each group. The treatment group was treated with paclitaxel combined with cisplatin, the control group was treated with cisplatin combined with 5-fluorouracil, the treatment effect and adverse reactions were observed in both groups. Results In the treatment group, 16 cases were completely relieved in 49 cases, 20 cases were partially relieved, 3 cases were stable and 10 cases were progressed. In the control group, 12 cases were completely relieved in 49 cases, 14 cases partially relieved, 10 cases stabilized and 13 cases progressed. The treatment group, the total effective rate was 73.5%, 53.0% in the control group, the treatment group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer has definite and safe clinical efficacy and is worth further promotion and application.